UBS Group
CSTL icon

UBS Group’s Castle Biosciences CSTL Stock Holding History

UBS Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,000
Closed -$1.01M – 9054
2020
Q4 		$1.01M Buy
+15,000
New +$813K ﹤0.01% 4020

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's CSTL Position: Q2 2026 in Review

UBS Group increased its Castle Biosciences (CSTL) stake by 82% in Q2 2026, buying an estimated $895K and bringing the position to 89,368 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #5064.

UBS Group first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $21.7M in Q4 2024. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • UBS Group held 89,368 shares of Castle Biosciences worth $2.13M as of Q2 2026.
  • UBS Group bought 40,205 Castle Biosciences shares in Q2 2026, an estimated $895K.
  • Castle Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5064 holding.
  • UBS Group first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • UBS Group's Castle Biosciences position peaked at $21.7M in Q4 2024.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.